# Basiliximab in Moderate to Severe Ulcerative Colitis

> **NCT00430898** · PHASE2 · COMPLETED · sponsor: **Cerimon Pharmaceuticals** · enrollment: 181 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Basiliximab

## Key facts

- **NCT ID:** NCT00430898
- **Lead sponsor:** Cerimon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 181 (ESTIMATED)
- **Last updated:** 2008-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430898, "Basiliximab in Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00430898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*